Copy to clipboard 
Catalyst OrthoScience recently closed an oversubscribed $12.5 million Series D round of funding, setting up the shoulder replacement company to expand its product lines and build out its infrastructure to support growth in the coming years.
The Naples, Florida-based company’s Archer portfolio recently introduced the Archer R1 Reverse Shoulder System and the Archer 3D Targeting imaging software. We spoke with Catalyst OrthoScience CEO Brian Hutchison about the current environment and state of funding.
How would you describe today’s funding environment?
Mr. Hutchison: Investors are very interested in innovative technologies and fast, sustainable growth. Companies that are truly being innovative and taking new approaches and can grow their market presence rapidly will be attractive to new investors. Catalyst OrthoScience checks both boxes. This is the second series of fundraising that has been oversubscribed, so investors see significant opportunity around our products and our growth potential.
Can you share details about your recent product introductions?
Mr. Hutchison: The Archer R1 Reverse Shoulder System is a single-tray arthroplasty system designed to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The Archer R1 system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone-sparing implants.
Archer 3D Targeting is imaging software designed to support preoperative planning for shoulder arthroplasty. Licensed in partnership with 3D-Shoulder, Archer 3D Targeting leverages two-dimensional images such as CT scans or MRIs. It develops a 3D model to help surgeons assess patient pathology and create a surgical plan in advance of the procedure.
We’ve seen a few smaller companies bring software to the market. Why did Catalyst prioritize development of imaging software?
Mr. Hutchison: Catalyst OrthoScience recognizes the growing demand for preoperative planning software in the shoulder market, so we partnered with 3D-Shoulder to develop Archer 3D Targeting. Surgeons see preoperative planning as a way to increase their efficiency in surgery, and many surgical residents and fellows are being trained using planning software. We expect to see expansion of this kind of technology in the future.
What are some of the primary trends you’re seeing in the shoulder replacement space today?
Mr. Hutchison: There are two primary trends in the shoulder replacement space we are seeing.
The first is the disappearance of the stem in the anatomic humeral implants themselves. Stemless devices, like ours, or devices with smaller stems allow for more bone preservation while also demonstrating strong clinical outcomes, surgical efficiency and positive patient experience.
The second is the rise of imaging technology. There is an increasing demand for imaging that supports efficiency in surgery.
What do you estimate is the size of the total shoulder replacement market?
Mr. Hutchison: It’s a great time to be in the markets that Catalyst OrthoScience serves. The extremities market is the fastest growing segment in orthopedics at around 6%, with shoulders representing the fastest segment in extremities at 8% growth. With the Archer CSR Total Shoulder System and Archer R1 Reverse System portfolio, Catalyst is addressing the two fastest growing segments of the $1 billion+ and growing shoulder arthroplasty market – stemless anatomic and reverse TSA.
Catalyst OrthoScience recently closed an oversubscribed $12.5 million Series D round of funding, setting up the shoulder replacement company to expand its product lines and build out its infrastructure to support growth in the coming years.
The Naples, Florida-based company’s Archer portfolio recently introduced the Archer R1 Reverse Shoulder...
Catalyst OrthoScience recently closed an oversubscribed $12.5 million Series D round of funding, setting up the shoulder replacement company to expand its product lines and build out its infrastructure to support growth in the coming years.
The Naples, Florida-based company’s Archer portfolio recently introduced the Archer R1 Reverse Shoulder System and the Archer 3D Targeting imaging software. We spoke with Catalyst OrthoScience CEO Brian Hutchison about the current environment and state of funding.
How would you describe today’s funding environment?
Mr. Hutchison: Investors are very interested in innovative technologies and fast, sustainable growth. Companies that are truly being innovative and taking new approaches and can grow their market presence rapidly will be attractive to new investors. Catalyst OrthoScience checks both boxes. This is the second series of fundraising that has been oversubscribed, so investors see significant opportunity around our products and our growth potential.
Can you share details about your recent product introductions?
Mr. Hutchison: The Archer R1 Reverse Shoulder System is a single-tray arthroplasty system designed to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The Archer R1 system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone-sparing implants.
Archer 3D Targeting is imaging software designed to support preoperative planning for shoulder arthroplasty. Licensed in partnership with 3D-Shoulder, Archer 3D Targeting leverages two-dimensional images such as CT scans or MRIs. It develops a 3D model to help surgeons assess patient pathology and create a surgical plan in advance of the procedure.
We’ve seen a few smaller companies bring software to the market. Why did Catalyst prioritize development of imaging software?
Mr. Hutchison: Catalyst OrthoScience recognizes the growing demand for preoperative planning software in the shoulder market, so we partnered with 3D-Shoulder to develop Archer 3D Targeting. Surgeons see preoperative planning as a way to increase their efficiency in surgery, and many surgical residents and fellows are being trained using planning software. We expect to see expansion of this kind of technology in the future.
What are some of the primary trends you’re seeing in the shoulder replacement space today?
Mr. Hutchison: There are two primary trends in the shoulder replacement space we are seeing.
The first is the disappearance of the stem in the anatomic humeral implants themselves. Stemless devices, like ours, or devices with smaller stems allow for more bone preservation while also demonstrating strong clinical outcomes, surgical efficiency and positive patient experience.
The second is the rise of imaging technology. There is an increasing demand for imaging that supports efficiency in surgery.
What do you estimate is the size of the total shoulder replacement market?
Mr. Hutchison: It’s a great time to be in the markets that Catalyst OrthoScience serves. The extremities market is the fastest growing segment in orthopedics at around 6%, with shoulders representing the fastest segment in extremities at 8% growth. With the Archer CSR Total Shoulder System and Archer R1 Reverse System portfolio, Catalyst is addressing the two fastest growing segments of the $1 billion+ and growing shoulder arthroplasty market – stemless anatomic and reverse TSA.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
CL
Carolyn LaWell is ORTHOWORLD's Chief Content Officer. She joined ORTHOWORLD in 2012 to oversee its editorial and industry education. She previously served in editor roles at B2B magazines and newspapers.
